BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 12, 2025
Home » Authors » Kim Coghill

Articles by Kim Coghill

Bioenvision Begins Pivotal Trial Of Clofarabine For AML In Europe

Aug. 11, 2004
By Kim Coghill

QLT Enlists Array To Assist With Work On Cancer Targets

Aug. 11, 2004
By Kim Coghill

Biotechnology Institute Promotes Student Interest In Life Sciences

Aug. 10, 2004
By Kim Coghill

Biotechnology Institute Promotes Student Interest In Life Sciences

Aug. 10, 2004
By Kim Coghill

CMS Posts List Of Changes For Drug Reimbursement, Services

Aug. 9, 2004
By Kim Coghill

CMS Posts List Of Changes For Drug Reimbursement, Services

Aug. 9, 2004
By Kim Coghill

Inex Loses GSK As Partner For Liposomal Cancer Drug

Aug. 5, 2004
By Kim Coghill

Inex Loses GSK As Partner For Liposomal Cancer Drug

Aug. 5, 2004
By Kim Coghill

Gilead's Combination HIV Drug, Truvada, Wins FDA Clearance

Aug. 4, 2004
By Kim Coghill
The FDA granted accelerated approval for Truvada, a fixed-dose combination of Gilead Sciences Inc.'s anti-HIV medications Emtriva and Viread. (BioWorld Today)
Read More

Gilead's Combination HIV Drug, Truvada, Wins FDA Clearance

Aug. 4, 2004
By Kim Coghill
The FDA granted accelerated approval for Truvada, a fixed-dose combination of Gilead Sciences Inc.'s anti-HIV medications Emtriva and Viread. (BioWorld Today)
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 142 143 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 12, 2025.
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Digital globe illustrating pharma trade, tariffs

    Navigating the Trump tariffs, part two: Amgen, Biogen, others

    BioWorld
    As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing